P. D. Ragonesi

428 total citations
10 papers, 360 citations indexed

About

P. D. Ragonesi is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, P. D. Ragonesi has authored 10 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in P. D. Ragonesi's work include Metabolism, Diabetes, and Cancer (6 papers), Diabetes Treatment and Management (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). P. D. Ragonesi is often cited by papers focused on Metabolism, Diabetes, and Cancer (6 papers), Diabetes Treatment and Management (6 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (5 papers). P. D. Ragonesi collaborates with scholars based in Italy. P. D. Ragonesi's co-authors include Angela D’Angelo, Giuseppe Derosa, Sibilla Salvadeo, Arrigo F.G. Cicero, Leonardina Ciccarelli, Ilaria Ferrari, Mario N. Piccinni, Alessia Gravina, Fabrizio Querci and Pamela Maffioli and has published in prestigious journals such as American Journal of Hypertension, Archives of Gerontology and Geriatrics and Diabetes Technology & Therapeutics.

In The Last Decade

P. D. Ragonesi

9 papers receiving 341 citations

Peers

P. D. Ragonesi
Thinzar Min United Kingdom
D. R. Hadden United Kingdom
Elizabeth M. Lamos United States
Lalita Prasad‐Reddy United States
K. Jameson United Kingdom
P. D. Ragonesi
Citations per year, relative to P. D. Ragonesi P. D. Ragonesi (= 1×) peers Oliver Schnell

Countries citing papers authored by P. D. Ragonesi

Since Specialization
Citations

This map shows the geographic impact of P. D. Ragonesi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. D. Ragonesi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. D. Ragonesi more than expected).

Fields of papers citing papers by P. D. Ragonesi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. D. Ragonesi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. D. Ragonesi. The network helps show where P. D. Ragonesi may publish in the future.

Co-authorship network of co-authors of P. D. Ragonesi

This figure shows the co-authorship network connecting the top 25 collaborators of P. D. Ragonesi. A scholar is included among the top collaborators of P. D. Ragonesi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. D. Ragonesi. P. D. Ragonesi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Derosa, Giuseppe, Pamela Maffioli, Ilaria Ferrari, et al.. (2010). Effects of One Year Treatment of Vildagliptin Added to Pioglitazone or Glimepiride in Poorly Controlled Type 2 Diabetic Patients. Hormone and Metabolic Research. 42(9). 663–669. 44 indexed citations
2.
Derosa, Giuseppe, Pamela Maffioli, Sibilla Salvadeo, et al.. (2010). Exenatide Versus Glibenclamide in Patients with Diabetes. Diabetes Technology & Therapeutics. 12(3). 233–240. 107 indexed citations
3.
Derosa, Giuseppe, Angela D’Angelo, Ivano Franzetti, et al.. (2009). Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. Journal of Clinical Pharmacy and Therapeutics. 34(3). 267–276. 14 indexed citations
4.
Derosa, Giuseppe, Angela D’Angelo, P. D. Ragonesi, et al.. (2007). Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Internal Medicine Journal. 37(2). 79–86. 37 indexed citations
5.
Derosa, Giuseppe, Elena Fogari, Angela D’Angelo, et al.. (2007). Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. Journal of Clinical Pharmacy and Therapeutics. 32(3). 261–268. 56 indexed citations
6.
Derosa, Giuseppe, Angela D’Angelo, P. D. Ragonesi, et al.. (2006). Metformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. Journal of Clinical Pharmacy and Therapeutics. 31(4). 375–383. 72 indexed citations
7.
Derosa, Giuseppe, Angela D’Angelo, P. D. Ragonesi, et al.. (2006). Effects of Rosiglitazone and Pioglitazone Combined with Metformin on the Prothrombotic State of Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome. Journal of International Medical Research. 34(5). 545–555. 18 indexed citations
8.
Derosa, Giuseppe, Sibilla Salvadeo, Angela D’Angelo, et al.. (2006). We-P11:65 Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. Atherosclerosis Supplements. 7(3). 360–360.
9.
Ragonesi, P. D., et al.. (1998). The impact of diabetes mellitus on quality of life in elderly patients. Archives of Gerontology and Geriatrics. 26. 417–422. 10 indexed citations
10.
Ragonesi, P. D.. (1998). B029 The effects of angiotensin II antagonist losartan on urinary albumin excretion in non insulin-dependent diabetes mellitus. American Journal of Hypertension. 11(4). 47A–47A. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026